Description
Researchers at St. Jude have invented a novel way to expand chimeric antigen receptor (CAR) T cells that work better for gene therapy. These T cells could form the basis of the next generation of CAR therapies that provide sustainable, superior antitumor activity.
Incorporating IL-12 in in vitro culture conditions results in the generation of stem cell memory (Tscm) cells, which possess an enhanced ability to eradicate tumors without reaching exhaustion.
Keywords
cer, immunology, chimeric antigen receptor (CAR), T cell, stem cell memory (Tscm) cells, epigenetic, IL-12, expansion
Granted Patents or Published Applications
Related Scientific References
Licensing Opportunities
St. Jude is seeking a partner or partners to help develop this for use with therapies. Contact: chad.riggs@stjude.org
Related Links
Technologies
- Attenuated Streptococcus Pneumoniae Strain and Vaccine for Protection Against Pneumococcal Disease (SJ-11-0001)
- Avian Influenza Vaccine (SJ-06-0013)
- Group B Streptococcus (GBS) Extracellular Matrix Adhesion Proteins (SJ-00-0030)
- Improved System for Generating Human Influenza Vaccine in Cell Tissue Culture (SJ-02-0016)
- Methods and Composition for Diagnosing and Preventing a Group B Streptococcal Infection (SJ-02-0032)
- Modified Influenza Virus for Monitoring and Improving Vaccine Efficiency (SJ-04-0033)
- Modified Sendai Virus Vaccine and Imaging Vector (SJ-11-0018)
- Reverse Genetics System for Generating RNA Viruses and Vaccines (SJ-00-0006)
- Screen to Identify Pneumococcal Proteins that Inhibit Transmission Rather than Invasive Disease (SJ-18-0045)
- Synthetic Vaccine and Immunogenic Fusion Proteins for Pneumococcal Infections, and uses (SJ-05-0036, SJ-10-0028, SJ-13-0032)
- Universal Influenza Vaccine (SJ-05-0040)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.